Management of mucopolysaccharidosis type IH (Hurler's syndrome) presenting in infancy with severe dilated cardiomyopathy: A single institution's experience

Journal of Inherited Metabolic Disease

Volumn 36, Issue 2, 2013, Pages 263-270

  Wiseman, Daniel H ^a   Mercer, Jean ^b   Tylee, Karen ^b   Malaiya, Nilima ^a   Bonney, Denise K ^a   Jones, Simon A ^b   Wraith, J Edmond ^b   Wynn, Robert F ^a  

^a ROYAL MANCHESTER CHILDREN S HOSPITAL   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; LARONIDASE; METHOTREXATE; PREDNISONE; THYMOCYTE ANTIBODY;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CHIMERA; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DISEASE SEVERITY; DRUG MEGADOSE; ELECTROCARDIOGRAM; ENGRAFTMENT; ENZYME REPLACEMENT; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; HEART CONTRACTION; HEART EJECTION FRACTION; HEART FAILURE; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HETEROZYGOSITY; HUMAN; HURLER SYNDROME; HYPERTENSION; INFANCY; INFANT; MAJOR CLINICAL STUDY; MALE; QRS COMPLEX; RETROSPECTIVE STUDY; SEPSIS; ST SEGMENT DEPRESSION; SYMPTOMATOLOGY; T WAVE INVERSION; CARDIOMYOPATHY, DILATED; COHORT ANALYSIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MUCOPOLYSACCHARIDOSIS I; NEWBORN; PATHOLOGY; PROCEDURES;

CARDIOMYOPATHY, DILATED; COHORT STUDIES; CYCLOPHOSPHAMIDE; ENZYME REPLACEMENT THERAPY; FEMALE; HEART FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; MUCOPOLYSACCHARIDOSIS I; RETROSPECTIVE STUDIES;

EID: 84879688298     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9500-3     Document Type: Article

References (39)

1. Aldenhoven M, Boelens JJ, de Koning TJ (2008) The clinical outcome of Hurler syndrome after stem cell transplantation. Biol Blood Marrow Transplant 14(5):485-498
2. Appelbaum F, Strauchen JA, Graw RG et al (1976) Acute lethal carditis caused by high-dose combination chemotherapy. A unique clinical and pathological entity. Lancet 1(7950):58-62
3. Boelens JJ, Wynn RF, O'meara A et al (2007) Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure. Bone Marrow Transplant 40(3):225-233
4. Boelens JJ, Rocha V, Aldenhoven M et al (2009) Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant 15(5):618-625
5. Braunlin EA, Stauffer NR, Peters CH et al (2003) Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol 92(7):882-886
6. Braunlin EA, Berry JM, Whitley CB (2006) Cardiac findings after enzyme replacement therapy for mucopolysaccharidosis type I. Am J Cardiol 98(3):416-418
7. Braunlin EA, Harmatz PR, Scarpa M et al (2011) Cardiac disease in patients with mucopolysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 34(6):1183-1197
8. Dangel JH (1998) Cardiovascular changes in children with mucopolysaccharide storage diseases and related disorders-clinical and echocardiographic findings in 64 patients. Eur J Pediatr 157(7):534-538
9. Donaldson MD, Pennock CA, Berry PJ, Duncan AW, Cawdery JE, Leonard JV (1989) Hurler syndrome with cardiomyopathy in infancy. J Pediatr 114(3):430-432
10. Dow E, Schulman H, Agura E (1993) Cyclophosphamide cardiac injury mimicking acute myocardial infarction. Bone Marrow Transplant 12(2):169-172
11. Gatzoulis MA, Vellodi A, Redington AN (1995) Cardiac involvement in mucopolysaccharidoses: effects of allogeneic bone marrow transplantation. Arch Dis Child 73(3):259-260
12. Gharib MI, Burnett AK (2002) Chemotherapy-induced cardiotoxicity: current practice and prospects of prophylaxis. Eur J Heart Fail 4(3):235-242
13. Goldberg MA, Antin JH, Guinan EC, Rappeport JM (1986) Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood 68(5):1114-1118
14. Gottdiener JS, Appelbaum FR, Ferrans VJ, Deisseroth A, Ziegler J (1981) Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 141(6):758-763
15. Gross DM, Williams JC, Caprioli C, Dominguez B, Howell RR (1988) Echocardiographic abnormalities in the mucopolysaccharide storage diseases. Am J Cardiol 61(1):170-176
16. Hinek A, Wilson SE (2000) Impaired elastogenesis in Hurler disease: dermatan sulfate accumulation linked to deficiency in elastin-binding protein and elastic fiber assembly. Am J Pathol 156(3):925-938
17. Hirth A, Berg A, Greve G (2007) Successful treatment of severe heart failure in an infant with Hurler syndrome. J Inherit Metab Dis 30(5):820
18. Hobbs JR, Hugh-Jones K, Barrett AJ et al (1981) Reversal of clinical features of Hurler's disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet 2(8249):709-712
19. Krivit W, Sung JH, Shapiro EG, Lockman LA (1995) Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant 4(4):385-392
20. Leal GN, de Paula AC, Leone C, Kim CA (2010) Echocardiographic study of paediatric patients with mucopolysaccharidosis. Cardiol Young 20(3):254-261
21. Moore D, Connock MJ, Wraith E, Lavery C (2008) The prevalence of and survival in Mucopolysaccharidosis I: Hurler, Hurler-Scheie and Scheie syndromes in the UK. Orphanet J Rare Dis 3:24
22. Neufield EM, J (2000) The mucopolysaccharidoses. In Scriver CS, WS ed. The metabolic and molecular bases of inherited disease: New York: McGraw Hill, 3421-3452
23. Palpant NJ, Bedada FB, Peacock B, Blazar BR, Metzger JM, Tolar J (2011) Cardiac disease in mucopolysaccharidosis type I attributed to catecholaminergic and hemodynamic deficiencies. Am J Physiol Heart Circ Physiol 300(1):H356-365
24. Pastores GM, Arn P, Beck M et al (2007) The MPS I registry: design, methodology, and early findings of a global disease registry for monitoring patients with Mucopolysaccharidosis Type I. Mol Genet Metab 91(1):37-47
25. Peters C, Shapiro EG, Anderson J et al (1998) Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood 91(7):2601-2608
26. Saif MA, Bigger BW, Brookes KE, et al (2012) Hematopoietic stem cell transplantation ameliorates the high incidence of neutralizing allo-antibodies observed in MPSI-Hurler after pharmacological enzyme replacement therapy. Haematologica doi: 10.3324/haematol.2011.058644
27. Santos GW, Sensenbrenner LL, Burke PJ et al (1972) The use of cyclophosphamide for clinical marrow transplantation. Transplant Proc 4(4):559-564
28. Schieken RM, Kerber RE, Ionasescu VV, Zellweger H (1975) Cardiac manifestations of the mucopolysaccharidoses. Circ 52(4):700-705
29. Shapiro EG, Lockman LA, Balthazor M, Krivit W (1995) Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J Inherit Metab Dis 18(4):413-429
30. Souillet G, Guffon N, Maire I et al (2003) Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant 31(12):1105-1117
31. Steinherz LJ, Steinherz PG, Mangiacasale D et al (1981) Cardiac changes with cyclophosphamide. Med Pediatr Oncol 9(5):417-422
32. Viñallonga X, Sanz N, Balaguer A, Miro L, Ortega JJ, Casaldaliga J (1992) Hypertrophic cardiomyopathy in mucopolysaccharidoses: regression after bone marrow transplantation. Pediatr Cardiol 13(2):107-109
33. Whitley CB, Belani KG, Chang PN et al (1993) Long-term outcome of Hurler syndrome following bone marrow transplantation. Am J Med Genet 46(2):209-218
34. Wraith JE (2001) Enzyme replacement therapy in mucopolysaccharidosis type I: progress and emerging difficulties. J Inherit Metab Dis 24(2):245-250
35. Wraith JE (2005) The first 5 years of clinical experience with laronidase enzyme replacement therapy for mucopolysaccharidosis I. Expert Opin Pharmacother 6(3):489-506
36. Wraith JE, Beck M, Lane R et al (2007) Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatr 120(1):e37-46
37. Wynn RF, Wraith JE, Mercer J et al (2009) Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr 154(4):609-611
38. Yano S, Moseley K, Pavlova Z (2009) Postmortem studies on a patient with mucopolysaccharidosis type I: Histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis Mar 27 (Epub ahead of print)
39. Yeh ETH, Tong AT, Lenihan DJ et al (2004) Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circ 109(25):3122-3131